← All verdicts
Verdict

Data Unavailable

Every analyzed stock in Data Unavailable — 2,921 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
"Data Unavailable" by: Model value (price vs DCF) Owner-earnings return (equity bond)

This lens: price against our probability-weighted DCF value (P/IV). Its own forward record began accruing on 2026-09-10 (daily snapshots); until a year of it exists, the panel below tests the nearest cousin we can measure point-in-time — cheap on book value — and says so.

Market state today: Calm — the S&P 500 closed 3.1% below its 1-year high (as of 2026-09-16). Our rule, the same one used to split every backtest on this site: sell-off = 10% or more below the 1-year high, borderline from 5%, calm otherwise. A further 7.2% fall from here would put us in a sell-off. Since 2006 the market has been in a sell-off 16.6% of the time, across 13 episodes (red bands).
2007200920112013201520172019202120232025
S&P 500 (SPY, adjusted) distance from its trailing 1-year high, weekly. Amber band: borderline (−5% to −10%). Red band: sell-off (below −10%). The dot is today. History to 2026-08-19 from the research database; today from the live feed.
Backtest · point in time · 8,702 entries in the study

Does this screen work? The record for exactly these filters

Screen tested: Proxy: price-to-book ≤ 1.2 (undervalued band has no point-in-time history yet) · bought the day of the annual report, held 12 months
Probable Buy every company that met this screen on the day it filed its annual report, hold 12 months: on average it beat the S&P 500 by +12.6 pts (1,427 entries, 311 companies, very unlikely to be luck). 50% of entries beat the S&P; 25% beat it by 30 points or more; 30% trailed it by 20 points or more. Owning everything instead averaged +1.7 pts, so the screen's edge is +10.9 pts.
+12.6 ptsvs S&P, average
50%beat the S&P
25%up 30+ pts vs S&P
30%down 20+ pts vs S&P
+14.0 ptsvs small caps, 12 mo
−15.1 pts 2019worst year to buy ?
6.1luck check ?
Does the holding period matter?3 mo: +2.3 pts 49% beat6 mo: +4.6 pts 49% beat12 mo: +12.6 pts 50% beat24 mo: +21.8 pts 46% beat3 yr, per yr: +1.3 pts 40% beat
Market state at entryCompany-yearsvs S&P 12 movs small caps
Calm ◀ today1,245+7.9 pts t 4.6+10.1 pts
Sell-off (S&P ≥10% off high)182+44.5 pts t 4.0+40.7 pts
Sector (SEC group)nvs S&P 12 mo3 yrs / yr
Industrials & manufacturing466+13.0 pts t 4.0−2.2 pts
Energy126+7.4 pts t 1.2−7.8 pts
Other115+8.4 pts t 1.8+3.8 pts
Tech hardware & semis113+10.9 pts t 1.6+2.3 pts
Services96+11.9 pts t 2.7+12.2 pts
Retail & consumer87+17.2 pts t 2.1+10.2 pts
Finance & real estate72−1.7 pts t -0.5−2.4 pts
Utilities65+5.6 pts t 0.6−1.2 pts
Construction53+13.2 pts t 1.7−2.4 pts
Biotech & pharma44+47.1 pts t 1.6+10.0 pts
Telecom & media43+14.0 pts t 0.7−6.3 pts
Software & IT services35+39.9 pts t 1.8+1.2 pts

Holds up out of sample? Before 2018: +10.7 pts (n 629, t 6.0). From 2018: +14.0 pts (n 798, t 4.1). Same sign in both halves.

Year2010201120122013201420152016201720182019202020212022202320242025
vs S&P+13 pts+5 pts+14 pts+18 pts−4 pts−4 pts+22 pts+12 pts−3 pts−15 pts+87 pts+8 pts+17 pts−9 pts−7 pts+15 pts
n254310610178841118178991297276108121115

Read the research behind this screen: Price-to-book still sorts, across all sizes → · Test your own combination in the Screen Lab →

Our model values are recomputed daily but were never stored historically, so this band cannot be backtested honestly yet. Daily snapshots began 2026-09-10; a true record accrues from there. Until then the nearest tested cousin is shown — cheap on book value — and labelled as a proxy. Point-in-time: each entry is one company bought at the first close after its 10-K filing date, using only filings available that day, held 12 months; result = total return minus SPY over the same months (vs IWM for 12 months; 3-yr annualised). Survivorship-tilted universe; no costs; read spreads, not levels. Educational, hypothetical, before costs.

Sort by: A–Z Riskiest Most overvalued Most shorted Buyers' strike Largest
BWLP
BW LPG Ltd
Valuation N/A
Industrials Risk 32 · Moderate
Price$25.13
Model IV—
P/IV—
Limited data — see page
BWMX
BETTERWARE DE MEXICO, S.A.P.I. DE C.V
Valuation N/A
Consumer Cyclical Risk 43 · Elevated
Price$15.54
Model IV—
P/IV—
Limited data — see page
BWNB
Babcock & Wilcox Enterprises, Inc.
Valuation N/A
Industrials Risk 27 · Moderate
Price$25.16
Model IV—
P/IV—
Market implies +16.6%/yr vs model +2.0% · above model
BWOW
Bitwise Dogecoin ETF
Valuation N/A
Financial Services Risk 36 · Moderate
Price$13.84
Model IV—
P/IV—
Limited data — see page
BXDC
Blackstone Digital Infrastructure Trust Inc.
Valuation N/A
Real Estate Risk 37 · Moderate
Price$19.52
Model IV—
P/IV—
Limited data — see page
BXSL
Blackstone Secured Lending Fund
Valuation N/A
Unknown Risk 64 · High
Price$24.41
Model IV—
P/IV—
Limited data — see page
BYND
BEYOND MEAT, INC.
Valuation N/A
Consumer Defensive Risk 65 · High
Price$10.31
Model IV—
P/IV—
Market implies +40.7%/yr vs model +2.0% · above model
BYSI
BeyondSpring Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$0.76
Model IV—
P/IV—
Market implies +30.5%/yr vs model +15.0% · above model
BZAI
Blaize Holdings, Inc.
Valuation N/A
Technology Risk 42 · Elevated
Price$0.56
Model IV—
P/IV—
Market implies +13.3%/yr vs model +15.0% · in line
CAAP
CORPORACION AMERICA AIRPORTS S.A.
Valuation N/A
Industrials Risk 37 · Moderate
Price$24.59
Model IV—
P/IV—
Limited data — see page
CABA
Cabaletta Bio, Inc.
Valuation N/A
Healthcare Risk 27 · Moderate
Price$2.73
Model IV—
P/IV—
Limited data — see page
CABR
Caring Brands, Inc.
Valuation N/A
Consumer Defensive Risk 44 · Elevated
Price$1.19
Model IV—
P/IV—
Market implies +123.3%/yr vs model +15.0% · above model
CADL
Candel Therapeutics, Inc.
Valuation N/A
Healthcare Risk 34 · Moderate
Price$10.55
Model IV—
P/IV—
Market implies +144.9%/yr vs model +2.0% · above model
CAE
CAE INC
Valuation N/A
Technology Risk 32 · Moderate
Price$23.71
Model IV—
P/IV—
Limited data — see page
CAF
Morgan Stanley China A Share Fund, Inc.
Valuation N/A
Unknown
Price$18.41
Model IV—
P/IV—
Limited data — see page
CALC
CalciMedica, Inc.
Valuation N/A
Healthcare Risk 35 · Moderate
Price$1.98
Model IV—
P/IV—
Limited data — see page
CAMP
Camp4 Therapeutics Corp
Valuation N/A
Healthcare Risk 35 · Moderate
Price$4.25
Model IV—
P/IV—
Market implies +35.3%/yr vs model +50.0% · below model
CAMT
CAMTEK LTD
Valuation N/A
Healthcare Risk 41 · Elevated
Price$147.97
Model IV—
P/IV—
Limited data — see page
CAN
Canaan Inc.
Valuation N/A
Financial Services Risk 42 · Elevated
Price$0.34
Model IV—
P/IV—
Market implies +30.5%/yr vs model +2.0% · above model
CANE
Teucrium Commodity Trust
Valuation N/A
Financial Services Risk 32 · Moderate
Price$11.52
Model IV—
P/IV—
Limited data — see page
CANF
Can-Fite BioPharma Ltd.
Valuation N/A
Healthcare Risk 33 · Moderate
Price$2.33
Model IV—
P/IV—
Market implies +30.1%/yr vs model +2.0% · above model
CAPN
Cayson Acquisition Corp
Valuation N/A
Financial Services Risk 27 · Moderate
Price$11.18
Model IV—
P/IV—
Limited data — see page
CAPNR
Cayson Acquisition Corp
Valuation N/A
Financial Services Risk 44 · Elevated
Price$0.11
Model IV—
P/IV—
Limited data — see page
CAPR
CAPRICOR THERAPEUTICS, INC.
Valuation N/A
Healthcare Risk 35 · Moderate
Price$8.56
Model IV—
P/IV—
Market implies +43.5%/yr vs model +15.0% · above model
CAPS
Capstone Holding Corp.
Valuation N/A
Industrials Risk 52 · Elevated
Price$0.17
Model IV—
P/IV—
Market implies +15.6%/yr vs model +3.0% · above model
CAQ
Cambridge Acquisition Corp.
Valuation N/A
Financial Services
Price$10.03
Model IV—
P/IV—
Limited data — see page
CAQUU
Cambridge Acquisition Corp.
Valuation N/A
Financial Services
Price$10.05
Model IV—
P/IV—
Limited data — see page
CAQUW
Cambridge Acquisition Corp.
Valuation N/A
Financial Services
Price$0.40
Model IV—
P/IV—
Limited data — see page
CAST
FreeCast, Inc.
Valuation N/A
Technology Risk 58 · Elevated
Price$1.41
Model IV—
P/IV—
Limited data — see page
CATX
Perspective Therapeutics, Inc.
Valuation N/A
Healthcare Risk 40 · Elevated
Price$2.81
Model IV—
P/IV—
Market implies +68.0%/yr vs model +15.0% · above model
CAVA
CAVA GROUP, INC.
Valuation N/A
Consumer Cyclical Risk 37 · Moderate
Price$49.99
Model IV—
P/IV—
Market implies +20.0%/yr vs model +23.9% · below model
CBIO
CRESCENT BIOPHARMA, INC.
Valuation N/A
Healthcare Risk 27 · Moderate
Price$19.41
Model IV—
P/IV—
Market implies +17.0%/yr vs model +50.0% · below model
CBRS
Cerebras Systems Inc.
Valuation N/A
Technology Risk 50 · Elevated
Price$191.93
Model IV—
P/IV—
Limited data — see page
CBUS
Cibus, Inc.
Valuation N/A
Basic Materials Risk 31 · Moderate
Price$1.57
Model IV—
P/IV—
Market implies +49.8%/yr vs model +5.0% · above model
CCCC
C4 Therapeutics, Inc.
Valuation N/A
Healthcare Risk 45 · Elevated
Price$3.51
Model IV—
P/IV—
Market implies +67.0%/yr vs model +2.0% · above model
CCD
Calamos Dynamic Convertible & Income Fund
Valuation N/A
Unknown
Price$23.98
Model IV—
P/IV—
Limited data — see page
CCEP
COCA-COLA EUROPACIFIC PARTNERS plc
Valuation N/A
Consumer Defensive Risk 58 · Elevated
Price$104.67
Model IV—
P/IV—
Limited data — see page
CCG
Cheche Group Inc.
Valuation N/A
Financial Services Risk 32 · Moderate
Price$14.61
Model IV—
P/IV—
Limited data — see page
CCHH
CCH Holdings Ltd
Valuation N/A
Consumer Cyclical Risk 27 · Moderate
Price$1.23
Model IV—
P/IV—
Market implies +43.8%/yr vs model +2.0% · above model
CCID
Carlyle Credit Income Fund
Valuation N/A
Unknown
Price$25.01
Model IV—
P/IV—
Limited data — see page
CCIF
Carlyle Credit Income Fund
Valuation N/A
Unknown
Price$2.55
Model IV—
P/IV—
Limited data — see page
CCII
Cohen Circle Acquisition Corp. II
Valuation N/A
Financial Services
Price$10.32
Model IV—
P/IV—
Limited data — see page
CCIX
Churchill Capital Corp IX/Cayman
Valuation N/A
Technology
Price$10.88
Model IV—
P/IV—
Limited data — see page
CCJ
CAMECO CORP
Valuation N/A
Basic Materials Risk 33 · Moderate
Price$93.26
Model IV—
P/IV—
Limited data — see page
CCM
Concord Medical Services Holdings Ltd
Valuation N/A
Healthcare Risk 28 · Moderate
Price$3.97
Model IV—
P/IV—
Market implies +14.4%/yr vs model +2.0% · above model
CCS
Century Communities, Inc.
Valuation N/A
Industrials Risk 37 · Moderate
Price$60.54
Model IV—
P/IV—
Market implies +7.2%/yr vs model +6.1% · in line
CCU
UNITED BREWERIES CO INC
Valuation N/A
Consumer Defensive Risk 40 · Elevated
Price$11.64
Model IV—
P/IV—
Limited data — see page
CCXI
Churchill Capital Corp XI
Valuation N/A
Financial Services
Price$12.32
Model IV—
P/IV—
Limited data — see page
CD
Chaince Digital Holdings Inc.
Valuation N/A
Financial Services Risk 44 · Elevated
Price$2.94
Model IV—
P/IV—
Market implies +89.1%/yr vs model +29.2% · above model
CDE
Coeur Mining, Inc.
Valuation N/A
Basic Materials Risk 29 · Moderate
Price$20.58
Model IV—
P/IV—
Market implies +58.5%/yr vs model +8.0% · above model
CDIO
Cardio Diagnostics Holdings, Inc.
Valuation N/A
Healthcare Risk 33 · Moderate
Price$2.03
Model IV—
P/IV—
Market implies +80.5%/yr vs model +50.0% · above model
CDLR
Cadeler A/S
Valuation N/A
Industrials Risk 51 · Elevated
Price$25.16
Model IV—
P/IV—
Limited data — see page
CDNL
Cardinal Infrastructure Group Inc.
Valuation N/A
Industrials Risk 55 · Elevated
Price$33.71
Model IV—
P/IV—
Limited data — see page
CDRO
Codere Online Luxembourg, S.A.
Valuation N/A
Communication Services Risk 58 · Elevated
Price$9.32
Model IV—
P/IV—
Limited data — see page
CDT
CDT Equity Inc.
Valuation N/A
Healthcare Risk 36 · Moderate
Price$0.25
Model IV—
P/IV—
Limited data — see page
CDTTW
CDT Equity Inc.
Valuation N/A
Healthcare Risk 46 · Elevated
Price$0.01
Model IV—
P/IV—
Limited data — see page
CDXS
CODEXIS, INC.
Valuation N/A
Basic Materials Risk 48 · Elevated
Price$1.47
Model IV—
P/IV—
Market implies +46.9%/yr vs model +0.0% · above model
CDZI
CADIZ INC
Valuation N/A
Utilities Risk 65 · High
Price$3.65
Model IV—
P/IV—
Limited data — see page
CDZIP
CADIZ INC
Valuation N/A
Utilities Risk 57 · Elevated
Price$22.20
Model IV—
P/IV—
Limited data — see page
CEE
CENTRAL & EASTERN EUROPE FUND, INC.
Valuation N/A
Unknown
Price$20.00
Model IV—
P/IV—
Limited data — see page